TrialLeukemia2016

Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.

D A Eichenauer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.